These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25941218)

  • 1. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
    Leyva-Grado VH; Tan GS; Leon PE; Yondola M; Palese P
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4162-72. PubMed ID: 25941218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.
    Vigil A; Frias-Staheli N; Carabeo T; Wittekind M
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.
    Nachbagauer R; Shore D; Yang H; Johnson SK; Gabbard JD; Tompkins SM; Wrammert J; Wilson PC; Stevens J; Ahmed R; Krammer F; Ellebedy AH
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.
    Sakabe S; Iwatsuki-Horimoto K; Horimoto T; Nidom CA; Le Mt; Takano R; Kubota-Koketsu R; Okuno Y; Ozawa M; Kawaoka Y
    Antiviral Res; 2010 Dec; 88(3):249-55. PubMed ID: 20849879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
    Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR
    J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates.
    Song A; Myojo K; Laudenslager J; Harada D; Miura T; Suzuki K; Kuni-Kamochi R; Soloff R; Ohgami K; Kanda Y
    Antiviral Res; 2014 Nov; 111():60-8. PubMed ID: 25218949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
    Haasbach E; Pauli EK; Spranger R; Mitzner D; Schubert U; Kircheis R; Planz O
    Antiviral Res; 2011 Sep; 91(3):304-13. PubMed ID: 21777621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo.
    Chen J; Yan B; Chen Q; Yao Y; Wang H; Liu Q; Zhang S; Wang H; Chen Z
    Arch Virol; 2014 Mar; 159(3):471-83. PubMed ID: 24057757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
    Paules CI; Lakdawala S; McAuliffe JM; Paskel M; Vogel L; Kallewaard NL; Zhu Q; Subbarao K
    J Infect Dis; 2017 Aug; 216(3):356-365. PubMed ID: 28633457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.
    Koudstaal W; Koldijk MH; Brakenhoff JP; Cornelissen LA; Weverling GJ; Friesen RH; Goudsmit J
    J Infect Dis; 2009 Dec; 200(12):1870-3. PubMed ID: 19911992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.
    Haasbach E; Reiling SJ; Ehrhardt C; Droebner K; Rückle A; Hrincius ER; Leban J; Strobl S; Vitt D; Ludwig S; Planz O
    Antiviral Res; 2013 Sep; 99(3):336-44. PubMed ID: 23811282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice.
    Son S; Ahn SB; Kim G; Jang Y; Ko C; Kim M; Kim SJ
    Antiviral Res; 2023 May; 213():105591. PubMed ID: 37003306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9.
    Li J; Zhang L; Bao L; Wang Y; Qiu L; Hu J; Tang R; Yu H; Shan J; Li Y; Qin C; Zhu F
    Chin Med J (Engl); 2022 Apr; 135(7):799-805. PubMed ID: 35671181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
    Chen Y; Qin K; Wu WL; Li G; Zhang J; Du H; Ng MH; Shih JW; Peiris JS; Guan Y; Chen H; Xia N
    J Infect Dis; 2009 Jan; 199(1):49-58. PubMed ID: 19032063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M; Kubo S; Tanaka M; Tobiume S; Tomozawa T; Yamashita M
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen.
    Cabral TM; Baig A; Berhane Y; Schmidt L; Hole K; Leith M; Kobasa D; Corbett CR
    J Virol Methods; 2014 Jan; 195():54-62. PubMed ID: 24060631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis.
    Clementi N; Criscuolo E; Castelli M; Clementi M
    New Microbiol; 2012 Oct; 35(4):399-406. PubMed ID: 23109007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks.
    Wollacott AM; Boni MF; Szretter KJ; Sloan SE; Yousofshahi M; Viswanathan K; Bedard S; Hay CA; Smith PF; Shriver Z; Trevejo JM
    EBioMedicine; 2016 Mar; 5():147-55. PubMed ID: 27077121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.